Page 5 - Cadila Healthcare

Cadila Healthcare's Q4 consolidated net profit falls 22% to Rs 460 cr

Total consolidated revenues for Q4FY19 for Zydus Cadila stood at Rs 3771.2 crore, up from Rs 3281.8 crore in the corresponding quarter last year

Weak India business, but Cadila Healthcare riding on strong US momentum

Benefits of the good US show were partly offset by declining domestic sales due to rationalisation of portfolio

Cadila Healthcare Q3 profit dips 6% to Rs 510.7 crore on rising expenses

Cadila Healthcare's total revenue rose to Rs 3,608.9 crore for the latest quarter

Cadila Healthcare subsidiary gets USFDA nod for ulcer treatment injection

Cadila Healthcare said the product will be manufactured at Liva Pharma's manufacturing facility at Vadodara, and is the first product to be approved from this site for marketing in the US

Cadila Healthcare posts 17% dip in Q2 net to Rs 4.1 bn; revenue down 8.1%

Ebitda dipped 20% YoY to Rs 6.87 billion

Cadila Healthcare plans to launch 50 products in US market in FY19

Of over 140 products in pipeline, at least 10 are para IV filings

Cadila Healthcare nears 52-week low post June quarter results

The stock slipped 5% to Rs 336, extending its 6% decline on Monday, trading close to its 52-week low of Rs 333 touched on July 20, 2018 on the BSE in intra-day trade.

Growth worries ahead for Cadila Healthcare after Q1 estimate miss

With mega products in US facing rising competition, analysts watchful on new launches

Cadila Healthcare Q1 net profit sees over three-fold jump to Rs 4.605 bn

Cadila launched nine new products in the US during the quarter

High base not growth deterrent for Cadila, high launches may drive earning

The stock, which has been trending down due to weak sentiment towards the pharma sector, could provide a good opportunity for investors at current valuations

Cadila Healthcare launch pipeline points to healthy outlook, stock gains

Strong Q4, healthy forecast could result in more upside for stock

Cadila Healthcare stock: Analysts see 20% compounded growth in US sales

While analysts have cut their forward net profit estimates to factor in the challenges, the correction in stock prices, according to them, is exaggerated

Cadila Healthcare gains 4% on USFDA nod for Metoprolol Succinate tablets

The stock was trading 4% higher at Rs 385 as compared to 0.01% rise in the S&P BSE Sensex at 09:45 am.

Cadila Healthcare turns focus on vaccines and biosimilars

Analysts expect the two segments to contribute 25% of domestic revenue in 2 years; vaccines contribute less than 1% of revenues at present, while biosimilars account for 4.5% of domestic revenues

Cadila Healthcare works to build Zydus brand

Cadila Laboratories was formed by two friends Ramanbhai Patel and IA Modi in 1952

Cadila Healthcare's Q2 net up 33% to Rs 503 cr

Cadila Healthcare Limited, also known as Zydus Cadila, reported a net profit growth of 33 per cent at Rs 503 crore in second quarter ended September 30, 2017, up from roughly Rs 378 crore for the said period last year.While total income from operations grew by 35 per cent year-on-year in Q2 to stand at Rs 3234 crore, Cadila Healthcare's business in the US posted sales of Rs 1,644 crore, up by 66 per cent, the company stated in an official communique.During the quarter, the company launched four new products in the US including Mesalamine Delayed Release 1.2 g tablets (generic version of Lialda ) with a 180 days exclusivity and received approval for 32 new products, including the generic version of Asacol HD (Mesalamine DR 800 mg tablets) and the generic version of Tamiflu suspension (Oseltamivir Powder for Oral Suspension 6 mg/ ml). The company filed nine additional ANDAs with the USFDA in the second quarter this fiscal.As against US operations, Cadila Healthcare saw its India ...

Competition clouds Cadila Healthcare's FY19 profit

Approval to Teva for key drug Lialda and sustained price erosion lead to stock downgrades

Zydus Cadila gets final FDA nod for skin disorder, hypertension drugs

While Desoximetasone ointment is used for treatment of symptoms of a skin disease, Labetalol hydrochloride tablets are used for the treatment of high blood pressure

Launches bring little cheer for Cadila

Pricing pressure is negating upsides from new products

Likely competition for generic Lialda bears on Cadila's stocks

Copy Begins/Cadila Healthcare's (Zydus Cadila) blockbuster drug the generic version of mesalamine (Lialda) is likely to face competition from the innovator itself as Irish pharma firm Shire Plc is expected to launch an authorised generic (AG) version of the drug in the US market soon. The ulcerative colitis drug is estimated to have a market size of $1.15 billion and Zydus was the first to file (FTF) an abbreviated new drug application (ANDA) for a generic version of Lialda in the US. The markets reacted by correcting in the stock price on Monday, which dipped around 5 per cent during day's trade on the BSE to Rs 477.25 a share. Zydus had commercially launched its mesalamine delayed release tablets (1.2 g) in the US market in mid July this year from its Moraiya facility near Ahmedabad. It was the first to file an ANDA for the generic version of the drug and is currently the only generic available to patients in the US. The drug is indicated for the treatment of mild to moderate ...